BINEX Co., Ltd.

A053030

KR7053030003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
15,660 ^KRW	+11.22%		-2.12%	+74.97%

03-15	BINEX Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-05	Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	MT

Tranche Update on BINEX Co., Ltd.'s Equity Buyback Plan announced on August 23, 2021.

September 03, 2021 at 03:02 am

From August 23, 2021 to August 31, 2021, the company has repurchased 283,286 shares, representing 0.91% for KRW 5,532.99 million. With this, the company has completed the repurchase of 283,286 shares, representing 0.91% for KRW 5,532.99 million under the buyback announced on August 23, 2021.

Latest news about BINEX Co., Ltd.

BINEX Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	03-05	MT
Sinjia Land Terminates Loan Deal With BINEX; Shares Up 6%	03-04	MT
Sinjia Land Scraps Deal to Buy Alternative Fuels Firm Over Unmet Closing Condition	01-01	MT
BINEX Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Sinjia Land Extends Long Stop Date to Acquire BINEX Singapore	22-09-29	MT
Sinjia Land Uses Portion of Proceeds from Share Placement for Deposit Payment to BINEX	22-07-01	MT
Singapore Shares End Week on High Note; Del Monte Pacific Shares Zoom 4% on Higher Fiscal Q4 Profit	22-06-24	MT
Sinjia Land to Make Refundable Deposit to BINEX in Relation to RTO Deal	22-06-24	MT
Sinjia Land to Acquire BINEX Singapore in RTO Deal	22-02-01	MT
With Investment Co., Ltd. acquired the remaining 16.63% stake in Rhinos Asset Management Co., Ltd from BINEX Co., Ltd..	21-09-30	CI
Exclusive: South Korea's GL Rapha to ship out 10 million Sputnik Light COVID-19 shots this month	21-09-14	RE
Boryung Pharmaceutical : S.Korea's GL Rapha to ship out 10 mln Sputnik Light COVID-19 shots this month	21-09-14	RE
Tranche Update on BINEX Co., Ltd.'s Equity Buyback Plan announced on August 23, 2021.	21-09-03	CI
BINEX Co., Ltd.'s Equity Buyback announced on August 23, 2021, has closed with 283,286 shares, representing 0.91% for KRW 5,532.99 million.	21-08-30	CI
BINEX Co., Ltd. announces an Equity Buyback for 283,286 shares.	21-08-22	CI
BINEX Co., Ltd. authorizes a Buyback Plan.	21-08-22	CI
An unknown buyer cancelled the acquisition of 6.97% stake in PeproMene Bio. Inc. from BINEX Co., Ltd..	21-05-10	CI
Noile-Immune Biotech Inc. announced that it has received ¥2.38 billion in funding from BINEX Co., Ltd., Binex Holdings Co., Ltd., Shibuya Corporation, The Dai-ichi Life Insurance Company, Limited, BiGEN Co., Ltd.	21-03-21	CI
Noile-Immune Biotech Inc announced that it has received ¥999.998803 million in funding from BINEX Co., Ltd.	21-03-11	CI
BINEX Co., Ltd. announced that it has received KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.	20-10-05	CI
BINEX Co., Ltd. announced that it expects to receive KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.	20-09-27	CI
PharmAbcine Signs CMO Contract with Binex	20-09-02	CI
PharmAbcine Signs Long-Term Contract Manufacturing Organization Agreement for Olinvacimab with Binex	20-06-26	CI
Genexine : South Korea's Genexine begins human trial of coronavirus vaccine	20-06-19	RE

Chart BINEX Co., Ltd.

Duration

Period

More charts

Company Profile

BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BINEX CO., LTD.	+74.97%	318M
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B

Other Pharmaceuticals

BINEX Co., Ltd.

Equities

A053030

KR7053030003

Pharmaceuticals

Tranche Update on BINEX Co., Ltd.'s Equity Buyback Plan announced on August 23, 2021.

Latest news about BINEX Co., Ltd.

Chart BINEX Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals